ATE460936T1 - Pyrazoloä1,5-aüpyrimidine derivate zur verwendung in der behandlung von morbus alzheimer und verwandten leiden - Google Patents

Pyrazoloä1,5-aüpyrimidine derivate zur verwendung in der behandlung von morbus alzheimer und verwandten leiden

Info

Publication number
ATE460936T1
ATE460936T1 AT07705350T AT07705350T ATE460936T1 AT E460936 T1 ATE460936 T1 AT E460936T1 AT 07705350 T AT07705350 T AT 07705350T AT 07705350 T AT07705350 T AT 07705350T AT E460936 T1 ATE460936 T1 AT E460936T1
Authority
AT
Austria
Prior art keywords
aüpyrimidine
alzheimer
disease
derivatives
treatment
Prior art date
Application number
AT07705350T
Other languages
English (en)
Inventor
Ian Churcher
Peter Hunt
Matthew Stanton
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE460936T1 publication Critical patent/ATE460936T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT07705350T 2006-01-27 2007-01-23 Pyrazoloä1,5-aüpyrimidine derivate zur verwendung in der behandlung von morbus alzheimer und verwandten leiden ATE460936T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0601638.0A GB0601638D0 (en) 2006-01-27 2006-01-27 Therapeutic treatment
PCT/GB2007/050036 WO2007085873A1 (en) 2006-01-27 2007-01-23 Treatment of alzheimer's disease and related conditions

Publications (1)

Publication Number Publication Date
ATE460936T1 true ATE460936T1 (de) 2010-04-15

Family

ID=36060954

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07705350T ATE460936T1 (de) 2006-01-27 2007-01-23 Pyrazoloä1,5-aüpyrimidine derivate zur verwendung in der behandlung von morbus alzheimer und verwandten leiden

Country Status (9)

Country Link
US (1) US20100240647A1 (de)
EP (1) EP1981509B1 (de)
JP (1) JP2009524635A (de)
AT (1) ATE460936T1 (de)
AU (1) AU2007209166A1 (de)
CA (1) CA2640386A1 (de)
DE (1) DE602007005353D1 (de)
GB (1) GB0601638D0 (de)
WO (1) WO2007085873A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100130737A1 (en) * 2005-02-18 2010-05-27 Takeda Pharmaceutical Company Limited Regulating Agent of GPR34 Receptor Function
EP2178375B1 (de) * 2007-07-20 2014-09-24 Merck Sharp & Dohme Corp. Pyrazol-[1,5-a]-pyrimidinderivate
JP5638961B2 (ja) * 2008-03-13 2014-12-10 ザ ジェネラル ホスピタル コーポレイション Ｂｍｐシグナル伝達経路のインヒビター
EP2320737B1 (de) 2008-08-05 2013-07-17 Merck Sharp & Dohme Corp. Pyrazolo-[1,5-a]-pyridine als mark-hemmer
EP2387315B1 (de) * 2009-01-16 2015-07-15 Merck Sharp & Dohme Corp. Imidazo-[1,2-a-]pyridine und imidazo-[1,2-b-]pyridazine als mark-hemmer
WO2011087999A1 (en) 2010-01-14 2011-07-21 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidines as mark inhibitors
WO2012045451A1 (en) * 2010-10-05 2012-04-12 Ludwig-Maximilians-Universitaet Muenchen Novel therapeutic treatment of progranulin-dependent diseases
US9682983B2 (en) 2013-03-14 2017-06-20 The Brigham And Women's Hospital, Inc. BMP inhibitors and methods of use thereof
WO2016011019A1 (en) 2014-07-15 2016-01-21 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting bmp

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1514558A1 (de) * 2003-09-15 2005-03-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Verwendung von MARKK oder MARKK-Antagonisten zur Behandlung von Pathologien die von einer erhöhten oder reduzierten Phosphorylierung des MARK- oder Tau-Proteins charakterisiert ist
EP1812440B1 (de) * 2004-11-04 2010-09-22 Vertex Pharmaceuticals, Inc. Als inhibitoren von proteinkinasen geeignete pyrazolo[1,5-a]pyrimidine

Also Published As

Publication number Publication date
WO2007085873A1 (en) 2007-08-02
GB0601638D0 (en) 2006-03-08
DE602007005353D1 (de) 2010-04-29
EP1981509A1 (de) 2008-10-22
CA2640386A1 (en) 2007-08-02
US20100240647A1 (en) 2010-09-23
JP2009524635A (ja) 2009-07-02
EP1981509B1 (de) 2010-03-17
AU2007209166A1 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
ATE460936T1 (de) Pyrazoloä1,5-aüpyrimidine derivate zur verwendung in der behandlung von morbus alzheimer und verwandten leiden
ATE497496T1 (de) 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
NO20082136L (no) 1,5-substituerte indol-2-yl-amidderivater
ATE516286T1 (de) 5-(ä1,3,4üoxadiazol-2-yl)-1h-indazol und 5-(ä1,3, 4üthiadiazol-2-yl)-1h-indazol derivate als sgk- inhibitoren zur behandlung von diabetes
TW200510334A (en) Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
ATE368031T1 (de) Neue gamma secretase inhibitoren
ATE492542T1 (de) Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas
NO20064456L (no) Thiadiazolidinoner som GSK-3 inhibitorer
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
ATE361067T1 (de) Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen
DE502004006619D1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
DE602004024880D1 (de) Azetidincarboxamid-derivate zur verwendung zur behandlung von cb1-rezeptor-vermittelten krankheiten
DE602005022113D1 (de) Phenyl)methanon-derivate als glycin-transporter 1 (glyt-1) hemmer zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
MX2010002938A (es) Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
ATE428711T1 (de) Substituierte 1h-pyrroloä3,2-b, 3,2-c und 2,3- cüpyridin-2-carbonsäureamide und verwandte analoga als inhibitoren von caseinkinase-i- epsilon
DE602007011975D1 (de) Thiadiazolderivate zur behandlung neurodegenerativer krankheiten
ATE512147T1 (de) Makrozyklische aminiopyridyl-beta-sekretase- hemmer zur behandlung von morbus alzheimer
ATE530525T1 (de) Piperidine und verwandte verbindungen zur behandlung von demenz
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
ATE549923T1 (de) Makrozyklische spiropiperidin-beta-sekretase- hemmer zur behandlung von morbus alzheimer
ATE437855T1 (de) (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit
ATE556053T1 (de) Piperidinderivate zur behandlung von alzheimer- krankheit

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties